Atopic Dermatitis

AD patients reflect high satisfaction, safety with dupilumab
December 18, 2020

A vast majority of patients with atopic dermatitis (AD) are satisfied with dupilumab (Dupixent, Sanofi and Regeneron) treatment, according to research presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress.

Identifying and improving quality of care in AD
December 17, 2020

A new innovative report identifies gaps and offers solutions for improving quality of care in atopic dermatitis (AD).

Three-year eczema data show sustained safety, efficacy
November 24, 2020

New study data shows that in adults with atopic dermatitis, dupilumab has performed as expected, with continued efficacy and no new safety signals.